Myriad Genetics (MYGN) Tops Q3 EPS by 3c, Offers Q4 & FY Guidance

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.41, $0.03 better than the analyst estimate of $0.38. Revenue for the quarter came in at $190.5 million versus the consensus estimate of $184.92 million.

GUIDANCE:

Myriad Genetics sees Q4 2016 EPS of $0.36-$0.38, versus the consensus of $0.42. Myriad Genetics sees Q4 2016 revenue of $186-188 million, versus the consensus of $197.94 million.

Myriad Genetics sees FY2016 EPS of $1.63-$1.65, versus the consensus of $1.66. Myriad Genetics sees FY2016 revenue of $753-755 million, versus the consensus of $757.67 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Arca Biopharma (ABIO) Reports Q1 Loss of $0.14
• Allison Transmission (ALSN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY24 Revenue Guidance